Insider Buying: TransMedics Group (NASDAQ:TMDX) Director Buys 1,336 Shares of Stock

Key Points

• Director David Weill purchased 1,336 TransMedics shares at an average price of $81.63, investing approximately $109,058 and increasing his direct ownership by 8.87% to 16,392 shares.
• TransMedics shares rose 4.5% to $85.86, while the company reported quarterly revenue of $189.95 million, above expectations, despite EPS of $0.44 missing the $0.50 consensus estimate.
• Institutional investors own 99.67% of the stock, and analysts remain mixed: six rate it Buy, six Hold, and one Sell, producing an overall Hold rating with a consensus price target of $124.18.

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) Director David Weill purchased 1,336 shares of the firm's stock in a transaction on Friday, September 11th. The shares were purchased at an average cost of $81.63 per share, for a total transaction of $109,057.68. Following the completion of the purchase, the director directly owned 16,392 shares in the company, valued at $1,338,078.96. The trade was a 8.87% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

TransMedics Group Trading Up 4.5%

Shares of TMDX traded up $3.68 on Monday, hitting $85.86. 942,830 shares of the stock traded hands, compared to its average volume of 1,033,064. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62. The firm has a market capitalization of $2.97 billion, a P/E ratio of 22.07, a P/E/G ratio of 1.13 and a beta of 1.90. The stock's 50 day moving average is $82.00 and its two-hundred day moving average is $90.26. TransMedics Group, Inc. has a 1 year low of $60.10 and a 1 year high of $156.00.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.06). The firm had revenue of $189.95 million during the quarter, compared to analysts' expectations of $184.00 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The firm's revenue was up 20.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.92 earnings per share. As a group, sell-side analysts predict that TransMedics Group, Inc. will post 1.46 earnings per share for the current year.

Institutional Investors Weigh In On TransMedics Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in TMDX. WINTON GROUP Ltd lifted its stake in shares of TransMedics Group by 52.4% in the 2nd quarter. WINTON GROUP Ltd now owns 18,203 shares of the company's stock valued at $1,209,000 after purchasing an additional 6,262 shares in the last quarter. Integrated Wealth Concepts LLC increased its position in TransMedics Group by 31.3% during the 2nd quarter. Integrated Wealth Concepts LLC now owns 2,877 shares of the company's stock worth $191,000 after purchasing an additional 686 shares in the last quarter. IFP Advisors Inc raised its holdings in TransMedics Group by 4.8% in the second quarter. IFP Advisors Inc now owns 4,652 shares of the company's stock valued at $309,000 after buying an additional 213 shares during the period. Corient Private Wealth LP lifted its position in TransMedics Group by 123.2% during the second quarter. Corient Private Wealth LP now owns 19,285 shares of the company's stock valued at $1,281,000 after buying an additional 10,644 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in TransMedics Group during the second quarter valued at approximately $551,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently commented on TMDX. UBS Group dropped their target price on TransMedics Group from $80.00 to $77.00 and set a "neutral" rating for the company in a research note on Wednesday, August 5th. Needham & Company LLC reissued a "buy" rating on shares of TransMedics Group in a research note on Friday. Canaccord Genuity Group restated a "buy" rating and issued a $124.00 price target on shares of TransMedics Group in a report on Tuesday, June 30th. TD Cowen reaffirmed a "buy" rating and set a $120.00 price objective on shares of TransMedics Group in a research note on Tuesday, September 8th. Finally, Stifel Nicolaus increased their price objective on shares of TransMedics Group from $75.00 to $80.00 and gave the stock a "hold" rating in a report on Thursday, June 18th. Six analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, TransMedics Group has an average rating of "Hold" and a consensus price target of $124.18.

About TransMedics Group

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation. The company develops and commercializes organ preservation and transport technologies designed to maintain donor organs in a functioning condition outside the body, potentially supporting evaluation and extending the time available for transplantation.

Its primary product is the Organ Care System (OCS), a portable perfusion platform that circulates oxygenated, nutrient-enriched fluid through donor organs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.